Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 4, 2013, Pages 236-240

  Adetunji, Adedotun A ^a   Achenbach, Chad ^b   Feinglass, Joseph ^b   Darin, Kristin M ^b   Scarsi, Kimberly K ^b   Ekong, Ernest ^c   Taiwo, Babafemi O ^b   Adewole, Isaac F ^d   Murphy, Robert ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b NORTHWESTERN UNIVERSITY   (United States)

^c APIN PUBLIC HEALTH INITIATIVES   (Nigeria)

^d UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

antiretroviral; ART; first line; treatment switch; virologic failure

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ANTIRETROVIRAL; ART; FIRST-LINE; TREATMENT SWITCH; VIROLOGIC FAILURE;

ADULT; ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; NIGERIA; OUTPATIENT CLINICS, HOSPITAL; RITONAVIR; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84880428822     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109712463733     Document Type: Article

References (18)

1. Hosseinipour MC, Van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral failure: high level NRTI resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009 ; 23 (9). 1127-1134
2. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for the second antiretroviral regimen for HIV-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007 ; 44 (3). 447-452
3. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006 ; 367 (9519). 1335-1342
4. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med. 2008 ; 168 (17). 1910-1918
5. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006 ; 3 (10). e417
6. Agwu A, Lindsey JC, Ferguson K, et al. Analyses of HIV-1 drug resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS. 2008 ; 22 (7). 545-552
7. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007 ; 21 (6). 721-732
8. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2007 ; 44 (3). 453-455
9. Goetz MB, Ferguson MR, Han X, et al. Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr. 2006 ; 43 (5). 541-549
10. National Agency for the Control of AIDS (NACA). Fact sheet 2011: ART in Nigeria. http://naca.gov.ng/content/view/417/lang,en/. Accessed February 4, 2012.
11. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011 ; 53 (12). 1283-1290
12. Federal Ministry of Health. National guidelines for HIV and AIDS treatment and care in adolescents and adults. Abuja, Nigeria, 2007. http://www.aidstar-one.com/national-guideline-or-hiv-and-aids-treatmentand-ca. Accessed February 4, 2012.
13. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS. 2008 ; 22 (11). 1305-1312
14. Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011 ; 14: 14
15. Dagnra AY, Vidal N, Mensah A, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc.. 2011 ; 14: 30
16. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009 ; 49 (12). 1928-1935
17. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 ; 58 (1). 23-31
18. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009.